

October 31, 2008

D. Western Therapeutics Institute, Inc.

1-18-11, Nishiki, Naka-ku, Nagoya-city, Aichi-pref. 460-0003 JAPAN

(Translation)

Notice regarding the grant of Rho-kinase inhibitors patent in Japan

D. Western Therapeutics Institute, Inc. ("DWTI" Yuichi Hidaka, CEO) has received a notification of an intent to grant a patent for selective inhibitors of Rho-kinase from Japan Patent Office, subsequent to "Notice regarding the grant of Rho-kinase inhibitors patent in Europe" dated October 31, 2008.

The patent applications for selective inhibitors of Rho-kinase were also filed in United States, as well as in Europe and Japan where this patent was granted as mentioned above.

Rho-kinase inhibitor is a compound, which is expected to show a large treatment effect for various diseases, by inhibiting Rho-kinase within living body

(Rho-kinase is one of the enzymes phosphorylating proteins called protein kinase, playing a role in intracellular signaling pathway which is essential for living.)

The invention, "selective inhibitors of Rho-kinase" is characterized by its highly selective inhibition of Rho-kinase. The compounds are expected as promising drug candidates for the treatment of various diseases such as glaucoma.

DWTI accelerates R&D activities for further innovation of protein kinase inhibitors including Rho-kinase inhibitors.

End